Company attributes
Other attributes
AOBiome is a biotechnology company headquartered in Newton, Massachusetts that was founded in 2013 by David Whitlock, James Heywood, Spiros Jamas.
The company is conducting clinical trials for treatments for acne, eczema, rosacea, allergic rhinitis, hypertension and migraine and the company is in preclinical stages in pulmonary and gut research. The company focuses on Ammonia Oxidizing Bacteria (AOB), which consumes nitric oxide (NO) and nitrite, a key signaling molecule in the circulatory system, central nervous system and as a systemic response in the human body.
AOB metabolism lowers pH and affects the microbiome, anti-inflammatory and vasodilatory compounds. The company claims that AOB correlates with a reduction in populations of Staphylococcus aureus and Propionibacterium acnes which are associated with eczema and acne.
AOBiome has a proprietary strain of AOB called B244 which is a strain of Nitrosomonas eutropha administered live in different potencies and formulations. In early 2019 AOBiome was issued a patent for the use of their AOB for treating eczema. The Phase 2 clinical trial for this treatment is expected to be complete in 2019. AOB treatment for acne has completed Phase 2 and Phase 3 is planned for 2019.
AOBiome invented an AOB spray containing a bacteria commonly found in dirt and untreated water called Nitrosomonas eutropha. The company produces microbiome-friendly products under the name Mother Dirt such as face and body cleanser and shampoo that clean the skin without killing AOB.
On March 21, 2013 AOBiome completed their seed funding round with $630,000 in funding from undisclosed investors.
On August 28, 2014 AOBiome completed their series A funding round with $576,500 in funding from undisclosed investors.
On December 31, 2014 AOBiome completed their series B funding round with $7.5 million in funding from Wakestream Ventures and Hedgewood.
On January 5, 2017 AOBiome completed their series C funding round with $30 million in funding from ICarbonX.
